New design for nutrients - Doppelherz sparkles with effervescent IML packaging from Sanner
Queisser Pharma uses Brilliance tubes and the well-tried desiccant closures from Sanner for their Doppelherz effervescent tablets.
Brilliance tubes provide a user-friendly and attractive all-in-one solution.
Food supplements are in vogue, especially effervescent tablets with vitamins and minerals. However, their practical packaging usually lacks an exciting design. To increase attention at point-of-sale for their “Doppelherz” effervescent tablets, Queisser Pharma now relies on the IML Brilliance tubes from Sanner. Combined with the proven desiccant closures, the manufacturer receives a user-friendly and attractive all-in-one solution.
In the highly competitive market for food supplements, effervescent tablets in tubes are considered one of the most effective and reliable dosage forms. In contrast to other packaging types, tubes do not crack or bend. The tablets cannot crumble; they are protected from light and moisture and have a long shelf life. The dietary supplements producer Queisser also relies on these advantages for the successful Doppelherz vitamins and minerals. Since the beginning of this year, customers receive an even more consumer-friendly and attractive packaging thanks to the Sanner Brilliance tubes.
Holistic concept from a single sourceQueisser supplies customers in Europe, Russia and Asia with effervescent tablets. The company has been using the proven and tested desiccant closures from Sanner for more than 15 years. Last year, they decided to switch to in-moldlabeling technology to achieve higher quality printing result and, above all, an improved readability for consumers. "With the Sanner Brilliance tubes, we offer our customers a high-end product in high-quality packaging," says Jürgen Hennings, Product Manager Marketing at Queisser Pharma. "The brilliant printing results increase the readability of the printed information, while providing a high quality impression and more attention at point-of-sale."
But these were not the only requirements: Queisser also needed a different tube length for the Doppelherz effervescent tablets. "Sanner was the only supplier able to promptly produce the according tube length with IML technology," Hennings explains. Instead of the conventional 144 millimeters, the Doppelherz tubes are 165 millimeters long. Sanner developed a new IML-capable tool specifically for the production of these tubes. “The combination of flexibility, quality and trust, together with the well-known desiccant closures were determining factors for our decision,” says Hennings. The company now receives a holistic effervescent packaging solution from a single source.
Flexible packaging with brilliant designCompared to conventional tubes printed with offset technology, IML tubes offer higher-quality, photorealistic printing with different surface structures. Up to eight colors and real metallic effects are possible. The good readability of the label, even for smaller font sizes, provides more space for product information, while the impact- and scratch-resistant decor ensures long durability.
The packaging can also be upgraded with additional features: consumers receive more detailed information via QR codes with just one click, while peel-off labels can be used as an additional information booklet. This way, customers get an attractive packaging with all the information they require in a small space – and manufacturers can increase brand loyalty thanks to a high-quality appearance and exceptional user-friendliness.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.